Looks like they are just giving the share holders more time and...

Looks like they are just giving the share holders more time and you just need to look at the quarterly and know RAP will be a going concern without the $700K loan for the quarter.

The first possibility is that that meeting should be permitted to continue, but there are at least three difficulties with that course. The first is that, as Mr Wood rightly points out, Pfizer Australia has made a best and final statement, and that may well be relevant to shareholders who are presently inclined to vote against the scheme because they hope that Pfizer Australia will make a better offer. Second, if an issue as to ResApp's ability to continue as a going concern without the loan agreement or the scheme exists, then fair disclosure of that matter to shareholders may provide a reason to vote in favour of the scheme, to obtain such value as may be available for their shares. Third, even apart from that issue, shareholders need to understand the terms of the loan agreement with Pfizer Australia, because the proposition that Pfizer Australia can require its repayment on five business days' notice may undermine other evidence given, which seeks to treat that agreement as not coercive in respect of shareholders' entry into the scheme. All of these matters suggest that a meeting, held this afternoon, without a proper understanding of those issues, would involve a real risk that shareholders are misinformed or not adequately informed of relevant matters.